Latest news for Grifols (OTC:GIFLF) Stock

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Comments

Grifols

News

Latest news for Grifols (OTC:GIFLF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga